1000341-55-8

Basic information

• Product Name: 6-chloro-3-iodo-1H-pyrrolo[3,2-c]pyridine
• Synonyms: 6-chloro-3-iodo-1H-pyrrolo[3,2-c]pyridine;1H-Pyrrolo[3,2-c]pyridine, 6-chloro-3-iodo-
• CAS NO: 1000341-55-8
• Molecular Formula: C7H4ClIN2
• Molecular Weight: 278.47753
• Mol File: 1000341-55-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 6-chloro-3-iodo-1H-pyrrolo[3,2-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-chloro-3-iodo-1H-pyrrolo[3,2-c]pyridine(1000341-55-8)
• EPA Substance Registry System: 6-chloro-3-iodo-1H-pyrrolo[3,2-c]pyridine(1000341-55-8)

Safety Data

• Hazardous Substances Data: 1000341-55-8(Hazardous Substances Data)

Usage

Uses

Due to the limited information available, specific applications of 6-chloro-3-iodo-1H-pyrrolo[3,2-c]pyridine cannot be accurately listed. However, given its classification within the pyrrolopyridine group, it is likely that this compound may have potential uses in the pharmaceutical industry, similar to other members of this class. Further research and development are required to explore and confirm its applications and therapeutic potential.

Upstream product

• 74976-31-1 6-chloro-1H-pyrrolo[3,2-c]pyridine 

Relevant articles and documents

AMINOPYRIMIDINE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS

This invention relates to novel compounds of formula (I) which are inhibitors of T790M containing EGFR mutants, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the prevention or treatment of cancer. (Formula I)

N-substituted azaindoles as potent inhibitors of Cdc7 kinase

Cdc7 kinase is responsible for the initiation and regulation of DNA replication and has been proposed as a target for cancer therapy. We have identified a class of Cdc7 inhibitors based on a substituted indole core. Synthesis of focused indole and azaindole analogs yielded potent and selective 5-azaindole Cdc7 inhibitors with improved intrinsic metabolic stability (ie 36). In parallel, quantum mechanical conformational analysis helped to rationalize SAR observations, led to a proposal of the preferred binding conformation in the absence of co-crystallography data, and allowed the design of 7-azaindole 37 as a second lead in this series.